Skip to main content
< Back to news
Credit: INBRAIN Neuroelectronics.
 26.11.2024

The Generalitat of Catalonia enters the capital of Inbrain Neuroelectronics

The public entity Avançsa -wholly owned by the Generalitat of Catalonia and attached to the Department of Business and Labor – has entered the capital of Inbrain Neuroelectronics through an investment agreement of 3 million euros. The company, based in the Barcelona Science Park, is a pioneer in the development of graphene-based neural platforms and has already successfully tested the application of its technology in humans in a clinical trial conducted at the Salford Royal Hospital in Manchester with brain cancer patients.

With this agreement, Avançsa incorporates Inbrain into the Extraordinary Projects Line, aimed at promoting disruptive initiatives within the framework of public-private and strategic collaborations for Catalonia.

On the other hand, Avançsa’s entry into the Inbrain’s capital consolidates the position of the Generalitat of Catalonia in a project born in 2020 as a spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Catalan Institution for Research and Advanced Studies (ICREA), which are currently part of the company’s shareholders.

Inbrain’s Brain Computer Interface Therapeutics (BCI-Tx) technology uses the exceptional properties of graphene, a Nobel Prize-winning material known for its strength, flexibility, and resolution of neural signals. The brain implant developed by the company is only 10 micrometers thick and is designed to decode and modulate neural activity safely and with unprecedented resolution, offering a new level of performance in the emerging field of precision neurology and minimizing the use of pharmacology.

Thanks to this agreement, Inbrain will accelerate the development of the BCI-Tx platform for diseases such as Parkinson’s, epilepsy, or stroke rehabilitation and will support ongoing clinical trials, allow for team expansion, and continue the development of the AI-driven platform for the treatment of neurological diseases.

Inbrain Neuroelectronics has been recognized by Norrsken in the Impact/100 2024 list, which includes the most innovative and impactful start-ups in the world, and is positioned internationally in the area of Brain Computer Interfaces (BCI) as a competitor to Neuralink, founded by Elon Musk.

» Press release [+]
» Related news [+]